- Astra Zeneca
- Glaxo Wellcome
- SmithKlineBeecham
- Eli Lilly
- Novartis
- Roche
- Serono
- St. Jude Medical
Another (dubious) cost of doing business
Addressing threats to health care's core values, especially those stemming from concentration and abuse of power - and now larger threats to the democracy needed to advance health and welfare. Advocating for accountability, integrity, transparency, honesty and ethics in leadership and governance of health care.
1 comment:
Thanks for this update.
I knew about the Swiss companies but not the others.
Looking at the kickbacks (sorry - "after sales service") it looks like around 10% of sales was the going rate.
The usual game would be that the negotiating pharma exec would also get a "reverse-kickback" of 10% of the 10% given to the Iraqi (this would make them dirty as well and reduce future whistleblowing opportunities).
Post a Comment